Latest insights into predictors of organ damage in childhood SLE

Childhood-onset systemic lupus erythematosus (cSLE) is a chronic, severe autoimmune disease that carries the chance of early organ damage. Identifying specific predictors in children is crucial to forestall such damage. At its 2024 Congress, EULAR – the European Alliance of Associations for Rheumatology – hosted a session on pediatric rheumatology, presenting latest work on the aspects related to the event of injury in cSLE, with a concentrate on corticosteroid therapies and maintaining low disease activity.

cSLE is a rare multisystem disease with significant morbidity, but evidence-based guidelines are few and treatment is due to this fact often based on clinical expertise. The EULAR/ACR-2019 criteria have shown sensitivity in cSLE patients, which can allow earlier detection of patients with single or major organ involvement. Nevertheless, identifying specific predictors on this vulnerable group is crucial to forestall long-term harm.

The brand new work, presented on the 2024 EULAR Congress, aimed to learn how clinical, demographic and treatment variables correlate with the evolution of injury in cSLE. Maria Hanif and her colleagues hoped that stratifying patients by average disease activity levels over the course of the disease would help them discover independent predictors of injury – even in children with low disease activity.

For this purpose, data were collected from 430 children participating within the British JSLE cohort study. Analyses were performed in all the cohort in addition to in two subgroups based on disease activity: low activity and moderate activity.

During a mean remark period of 46 months, 23% of kids experienced organ damage. Inside all the cohort, multivariable analyses showed that three aspects were related to the event of injury: methylprednisolone exposure, time-corrected mean Physician’s Global Assessment (PGA) rating, and adjusted mean SLE Disease Activity Index (AMS) rating. Looking only on the subgroup with moderate to high disease activity, 28.1% experienced damage—but the identical three aspects were identified as predictors. Throughout the subgroup with low disease activity, 20.5% of kids experienced latest damage, and here too, methylprednisolone exposure and time-corrected mean PGA rating were related to the event of injury, but not the AMS rating.

This study highlights the role of corticosteroid exposure as a major and potentially modifiable risk consider cSLE and suggests that dosing limits for kids have to be reviewed as these are typically above adult recommendations. As well as, a direct association between disease activity and harm was found, with each unit increase within the SLE Disease Activity Index (SLEDAI) increasing the chance of harm by 13-15% in patients with moderate to high activity. This was not observed in patients with an AMS of 4 or less, suggesting that low disease activity – maintained by treat-to-target strategies – could substantially reduce the chance of harm. These findings highlight the necessity for updated treatment protocols that limit corticosteroid use while effectively treating disease activity.